Kinnate Biopharma Inc (KNTE) News

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 14D9 - Solicitation, recommendation statements

Form SC14D9C - Written communication relating to third party tender offer

Form 8-K - Current report

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global...

Form SC14D9C - Written communication relating to third party tender offer

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc. PR Newswire NEW YORK, Feb. 16, 2024 NEW YORK, Feb. 16...

Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law Firm

Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 16...

Form 8-K - Current report